



AMERICAN JOURNAL OF PHARMTECH RESEARCH

Journal home page: <http://www.ajptr.com/>

Pharmacokinetic and Pharmacodynamic Interactions between Glimepiride-Metformin Combination and Angiotensin Receptor Blockers: Necessity, Current Evidence and Future Research Directions

Nagaraju B^{1*}, Anilkumar KV¹, Samhitha J¹, Padmavathi GV², Neerajraj GN³

1. Department of Pharmacology, Visveswarapura Institute of Pharmaceutical Sciences, BSK-2nd Stage, Bengaluru-560070

2. Dept. of Medical Surgical Nursing, Aditya College of Nursing, Kogilu, Bengaluru-560064

3. UG-Medical, ESIC Medical College & PGIMSR, Rajajinagar, Bengaluru-560010

ABSTRACT

Type 2 diabetes mellitus (T2DM) frequently coexists with hypertension, substantially increasing the risk of cardiovascular morbidity, mortality, and progressive renal disease. Contemporary management of these comorbid conditions relies heavily on polypharmacy, with oral antidiabetic drugs and antihypertensive agents prescribed concomitantly for prolonged durations. Among antidiabetic therapies, the fixed-dose combination of glimepiride and metformin remains widely used because it addresses both insulin resistance and impaired insulin secretion. Angiotensin receptor blockers (ARBs) are commonly recommended antihypertensive agents in patients with T2DM due to their established renoprotective and cardioprotective benefits. However, accumulating experimental and clinical evidence suggests that ARBs are not metabolically inert; instead, they may influence glucose homeostasis, insulin sensitivity, and the pharmacokinetic disposition of antidiabetic drugs. These effects raise clinically relevant concerns regarding potential pharmacokinetic and pharmacodynamic interactions when ARBs are co-administered with glimepiride-metformin combinations. Preclinical investigations have demonstrated enhanced hypoglycemic responses when certain ARBs, such as losartan and telmisartan, are combined with glimepiride-metformin, possibly due to synergistic pharmacodynamic actions or alterations in drug metabolism and transport. Telmisartan, in particular, exhibits partial peroxisome proliferator-activated receptor gamma (PPAR- γ) agonist activity, which may confer additional insulin-sensitizing effects. Clinical evidence, however, remains limited and inconsistent, with some studies suggesting modest improvements in glycemic control and others indicating an increased risk of hypoglycemia, especially in regimens containing sulfonylureas. Moreover, most available studies lack integrated pharmacokinetic-pharmacodynamic assessments and fail to reflect chronic real-world combination therapy. This review critically synthesizes current preclinical and clinical evidence on pharmacokinetic and pharmacodynamic interactions between glimepiride-metformin combinations and ARBs. It highlights existing knowledge gaps, underscores the clinical necessity for systematic and ARB specific evaluation, and proposes future research directions aimed at optimizing safety and therapeutic outcomes in patients with coexisting T2DM and hypertension.

Keywords: Type 2 diabetes mellitus; Glimepiride; Metformin; Angiotensin receptor blockers; Drug-drug interactions; Pharmacokinetics; Pharmacodynamics; Polypharmacy; Hypoglycemia

*Corresponding Author Name : Nagaraju B

Received 25 April 2026, Accepted 19 May 2026

Please cite this article as: Nagaraju B *et al.*, Pharmacokinetic and Pharmacodynamic Interactions between Glimepiride-Metformin Combination and Angiotensin Receptor Blockers: Necessity, Current Evidence and Future Research Directions. American Journal of PharmTech Research 2026.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is one of the most prevalent noncommunicable diseases worldwide and represents a major public health challenge¹. Characterized by chronic hyperglycemia resulting from insulin resistance, impaired pancreatic β -cell function, or a combination of both, T2DM is associated with significant long-term microvascular and macrovascular complications². The global burden of T2DM has increased dramatically over recent decades, driven by urbanization, sedentary lifestyles, population aging, obesity, and dietary transitions. According to epidemiological projections, the prevalence of T2DM is expected to continue rising, particularly in low- and middle-income countries, further intensifying its clinical and economic impact³.

Hypertension is one of the most common comorbid conditions in patients with T2DM, affecting approximately 50-70% of this population. The coexistence of diabetes and hypertension is not merely coincidental; rather, these conditions share overlapping pathophysiological mechanisms, including endothelial dysfunction, oxidative stress, low-grade inflammation, insulin resistance, and activation of the renin angiotensin aldosterone system (RAAS)⁴. When present together, T2DM and hypertension exert synergistic adverse effects, markedly increasing the risk of cardiovascular events such as myocardial infarction, stroke, and heart failure, as well as accelerating the progression of diabetic nephropathy to end-stage renal disease⁵.

Optimal management of patients with T2DM and hypertension therefore requires comprehensive and sustained control of glycemia, blood pressure, and associated cardiovascular risk factors. In clinical practice, this goal is typically achieved through long-term polypharmacy, often involving combinations of oral antidiabetic agents, antihypertensive drugs, lipid-lowering therapies, and antiplatelet agents⁶. While such an approach is therapeutically necessary, it inevitably increases the potential for drug-drug interactions (DDIs), which may compromise treatment efficacy or patient safety. In this context, understanding the pharmacokinetic and pharmacodynamic interactions between commonly co-prescribed drugs is of paramount importance.

POLYPHARMACY AND DRUG-DRUG INTERACTIONS IN DIABETIC HYPERTENSIVE PATIENTS

Polypharmacy is an inherent feature of modern T2DM management, particularly in patients with multiple comorbidities such as hypertension, dyslipidemia, and cardiovascular disease. Although the use of multiple medications is often unavoidable, it is associated with increased risks of adverse drug reactions, medication nonadherence, and clinically significant DDIs⁷. Drug-drug interactions can broadly be categorized as pharmacokinetic or pharmacodynamic. Pharmacokinetic

interactions occur when one drug alters the absorption, distribution, metabolism, or excretion of another, leading to changes in systemic exposure. Pharmacodynamic interactions, on the other hand, arise when drugs influence similar physiological pathways or targets, resulting in additive, synergistic, or antagonistic effects⁸.

In patients with diabetes, DDIs that affect glucose homeostasis are of particular concern, as they may precipitate hypoglycemia or exacerbate hyperglycemia. Sulfonylureas, including glimepiride, are especially susceptible to interactions because of their narrow therapeutic index and metabolism via hepatic cytochrome P450 enzymes, particularly CYP2C9⁹. Metformin, while generally considered safe, depends on renal excretion through organic cation transporters, making it vulnerable to interactions that alter renal function or transporter activity. Antihypertensive agents that influence hepatic enzyme activity, renal hemodynamics, or insulin sensitivity may therefore modify the pharmacokinetic or pharmacodynamic profiles of antidiabetic drugs¹⁰.

RATIONALE FOR GLIMEPIRIDE-METFORMIN COMBINATION THERAPY

Metformin is universally recommended as the first-line pharmacotherapy for T2DM owing to its efficacy, safety profile, low cost, and favorable effects on body weight and cardiovascular outcomes¹¹. It primarily acts by suppressing hepatic gluconeogenesis, enhancing peripheral insulin sensitivity, and improving glucose uptake in skeletal muscle. Importantly, metformin does not stimulate insulin secretion, thereby conferring a minimal risk of hypoglycemia when used as monotherapy¹².

As T2DM progresses, however, progressive β -cell dysfunction often necessitates the addition of other glucose-lowering agents to achieve and maintain glycemic targets. Sulfonylureas remain widely used add-on therapies, particularly in resource-limited settings, because of their potent glucose-lowering effects and affordability¹³. Glimepiride, a third-generation sulfonylurea, stimulates insulin secretion in a glucose-dependent manner by inhibiting ATP-sensitive potassium channels in pancreatic β -cells. Compared with older sulfonylureas, glimepiride is associated with a lower risk of severe hypoglycemia when appropriately dosed and may exert additional extra pancreatic insulin-sensitizing effects¹⁴.

The fixed-dose combination of glimepiride and metformin offers several advantages, including complementary mechanisms of action, improved glycemic control, reduced pill burden, and enhanced patient adherence. Nevertheless, the inclusion of a sulfonylurea increases the risk of hypoglycemia, particularly when combined with other agents that influence glucose metabolism or drug disposition. This risk underscores the importance of evaluating potential interactions with commonly co-prescribed antihypertensive drugs such as ARBs¹⁵.

PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF GLIMEPIRIDE

Glimepiride is rapidly and almost completely absorbed following oral administration, with peak plasma concentrations typically achieved within two to three hours. It is highly bound to plasma proteins, primarily albumin, which may predispose it to displacement interactions. Glimepiride undergoes extensive hepatic metabolism, mainly via the CYP2C9 isoenzyme, to form active and inactive metabolites. Consequently, drugs that inhibit or induce CYP2C9 can significantly alter glimepiride plasma concentrations, potentially leading to exaggerated hypoglycemic effects or reduced therapeutic efficacy¹⁶.

Pharmacodynamically, glimepiride enhances insulin secretion and increases peripheral glucose uptake. While its glucose-dependent mechanism reduces the risk of hypoglycemia compared with older sulfonylureas, excessive systemic exposure or synergistic pharmacodynamic interactions can still result in prolonged and severe hypoglycemia, particularly in elderly patients, those with renal impairment, or individuals receiving concomitant interacting medications¹⁷.

PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF METFORMIN

Metformin exerts its antihyperglycemic effects primarily by inhibiting hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose utilization. Unlike sulfonylureas, metformin does not increase insulin secretion and is therefore associated with a negligible risk of hypoglycemia when used alone¹⁸.

Pharmacokinetically, metformin is absorbed mainly from the small intestine and is not metabolized. It is eliminated unchanged via renal excretion through glomerular filtration and active tubular secretion mediated by organic cation transporters, including OCT1, OCT2, and multidrug and toxin extrusion proteins. Drugs that impair renal function or inhibit these transporters may increase metformin exposure, raising the risk of adverse effects such as lactic acidosis. Thus, agents that alter renal hemodynamics, including ARBs, may indirectly influence metformin pharmacokinetics¹⁹.

ANGIOTENSIN RECEPTOR BLOCKERS IN DIABETIC HYPERTENSION

ARBs selectively block angiotensin II type 1 (AT1) receptors, resulting in vasodilation, reduced aldosterone secretion, and decreased sympathetic activity. In patients with T2DM, ARBs are preferred antihypertensive agents because they reduce intraglomerular pressure, attenuate proteinuria, and slow the progression of diabetic nephropathy. Large clinical trials have demonstrated their benefits in reducing cardiovascular and renal outcomes in this high-risk population²⁰.

Beyond their hemodynamic effects, ARBs exhibit pleiotropic metabolic actions. Several ARBs have been shown to improve insulin sensitivity, reduce oxidative stress, and modulate inflammatory pathways. Telmisartan is unique among ARBs in that it acts as a partial agonist of PPAR- γ , a nuclear receptor involved in glucose and lipid metabolism. This property may confer additional metabolic benefits, distinguishing telmisartan from other ARBs such as losartan, valsartan, olmesartan, and candesartan²¹.

CURRENT EVIDENCE OF INTERACTIONS BETWEEN GLIMEPIRIDE-METFORMIN AND ARBs

Preclinical studies have provided important insights into potential interactions between glimepiride-metformin combinations and ARBs. Experimental investigations in animal models have demonstrated that co-administration of losartan with glimepiride-metformin enhances hypoglycemic effects under both normal and diabetic conditions. These findings suggest a pharmacodynamic synergy, possibly mediated by improved insulin sensitivity or modulation of RAAS-related pathways, as well as potential pharmacokinetic alterations²².

Similar observations have been reported with telmisartan, where enhanced glucose-lowering effects have been attributed to its partial PPAR- γ agonist activity. Some studies have also suggested that telmisartan may alter the pharmacokinetics of metformin, potentially reducing its bioavailability while maintaining or enhancing overall glycemic control. However, the clinical relevance of these findings remains uncertain²³.

Clinical evidence regarding these interactions is limited and often inconsistent. Some clinical studies and observational analyses have reported modest improvements in glycemic parameters in patients receiving ARBs alongside antidiabetic therapy. Conversely, other reports have raised concerns about an increased risk of hypoglycemia, particularly when sulfonylureas are part of the regimen. These discrepancies may reflect differences in study design, patient populations, duration of therapy, and the specific ARBs evaluated²⁴.

LIMITATIONS OF EXISTING RESEARCH

Despite growing interest in the metabolic effects of ARBs, the existing literature is fragmented and characterized by several limitations. Most studies are short-term, focus on monotherapy, or evaluate isolated pharmacodynamic outcomes without integrated pharmacokinetic assessment²⁵. There is a paucity of well-designed studies examining chronic co-administration of glimepiride-metformin combinations with specific ARBs under real-world conditions. Additionally, the roles of drug transporters, pharmacogenetic variability, and patient-specific factors remain largely unexplored.

NECESSITY AND SIGNIFICANCE OF SYSTEMATIC EVALUATION

Given the widespread concurrent use of glimepiride-metformin combinations and ARBs in clinical practice, systematic evaluation of their interactions is essential. Clarifying the mechanisms and clinical relevance of these interactions will enable clinicians to balance potential metabolic benefits against the risk of adverse outcomes such as hypoglycemia. Comparative evaluation of different ARBs may also help identify agents with more favorable metabolic profiles, thereby guiding individualized therapy in patients with T2DM and hypertension.

FUTURE RESEARCH DIRECTIONS

Future research should prioritize long-term, well-controlled clinical trials that integrate pharmacokinetic and pharmacodynamic assessments of glimepiride-metformin and ARB combinations. Studies should explore ARB-specific effects, transporter-mediated interactions, and the influence of genetic polymorphisms on drug response. Real-world pharmacovigilance and observational studies will also be critical for capturing rare but clinically significant adverse events. Such comprehensive research efforts will support evidence-based, personalized management strategies for patients with coexisting T2DM and hypertension.

CONCLUSION

The concomitant use of glimepiride-metformin combinations and ARBs is common and often therapeutically justified in patients with T2DM and hypertension. However, emerging evidence indicates that these combinations may be associated with clinically relevant pharmacokinetic and pharmacodynamic interactions. While certain ARBs, particularly telmisartan, may offer additional metabolic benefits, the potential risk of hypoglycemia warrants careful consideration. This review highlights the urgent need for systematic and comprehensive research to elucidate these interactions and to inform safer, more effective therapeutic strategies in this high-risk patient population.

REFERENCES

1. Murthy TEGK, Mayuren C. Pharmacokinetics of Gliclazide Alone and in Combination with Irbesartan in Rabbits. *Research Journal of Pharmacy and Technology* 2008; 1(4):418-21.
2. Murthy TEGK, Kommineni MK, CandasamyMayuren. Influence of losartan on the hypoglycemic activity of glimepiride in normal and diabetic rats. *Ther Adv Endocrinol Metab* 2013; 4(5): 133-8.
3. Anusha A, Dudhipala N, Boini KV, Puchchakayala G, Influence of Single and Multi-Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of Irbesartan in

- Normal and Hypertensive Rats. High Blood Pressure & Cardiovascular Prevention June 2017; 24(2):179-85.
4. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and cardiovascular disease: Clinical Insights and Vascular Mechanisms. *Can J Cardiol.* 2018 May;34(5):575-584.
 5. Liu Y, Li J, Dou Y, Ma H. Impacts of type 2 diabetes mellitus and hypertension on the incidence of cardiovascular diseases and stroke in China real-world setting: a retrospective cohort study. *BMJ Open.* 2021 Nov 29;11(11):e053698.
 6. Handelsman Y, Jellinger PS. Overcoming obstacles in risk factor management in type 2 diabetes mellitus. *J Clin Hypertens (Greenwich).* 2011 Aug;13(8):613-20.
 7. Dobrica EC, Gaman MA, Cozma MA, Bratu OG, Pantea Stoian A, Diaconu CC. Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department. *Medicina (Kaunas).* 2019 Aug 3;55(8):436.
 8. Niu J, Straubinger RM, Mager DE. Pharmacodynamic Drug-Drug Interactions. *Clin Pharmacol Ther.* 2019 Jun;105(6):1395-406.
 9. Zhou X, Zhang R, Zou Z, Shen X, Xie T, Xu C, Dong J, Liao L. Hypoglycaemic effects of glimepiride in sulfonylurea receptor 1 deficient rat. *Br J Pharmacol.* 2019 Feb;176(3):478-90.
 10. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. *Drug Metab Pharmacokinet.* 2005 Oct;20(5):379-86.
 11. Nagaraju B, Anil Kumar KV, Ravindran M, Shekar HS, Anatha NN, Padmavathi GV. Multicenter study on prescribing practice of oral hypoglycemic agents in selected hospitals at Bangalore city. *Eur J Pharm Med Research.* 2016;3(2):210-13.
 12. Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, Haque M. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. *Drug Des Devel Ther.* 2023 Jun 26;17:1907-32.
 13. Sayyed Kassem L, Rajpal A, Barreiro MV, Ismail-Beigi F. Beta-cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced? *J Diabetes.* 2023 Oct;15(10):817-37.
 14. Kalra et al., Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. *Indian Journal of Endocrinology and Metabolism.* Sep-Oct 2015.; 19(5):p 577-96.
 15. Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, Chung CH, Park JH, Jang HC, Choi DS. Efficacy of glimepiride/metformin fixed-dose combination vs metformin

- uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. *J Diabetes Investig.* 2014 Nov;5(6):701-8.
16. Basit A, Riaz M, Fawwad A. Glimperide: evidence-based facts, trends, and observations (GIFTS). [corrected]. *Vasc Health Risk Manag.* 2012;8:463-72.
17. Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, Häring HU. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. *Diabetes Care.* 2002 Nov;25(11):2065-73.
18. Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. *Diabetes Care.* 1994, 17:1100-9.
19. Yang Y, Zhang Z, Li P, Kong W, Liu X, Liu L. A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators. *Pharmaceutics.* 2021 May 11;13(5):698.
20. Nagaraju B, Anilkumar KV, Ramachandrasetty S, Ravindran M, Shekar HS, Satyanarayana S, et al. Patterns of antihypertensive mono therapy in hypertensive Type-2 diabetics on glimepiride metformin combination. *Int J Pharmacother.*2016;6:19-23.
21. Liu T, Cui L, Xue H, Yang X, Liu M, Zhi L, Yang H, Liu Z, Zhang M, Guo Q, He P, Liu Y, Zhang Y. Telmisartan Potentiates Insulin Secretion via Ion Channels, Independent of the AT1 Receptor and PPAR γ . *Front Pharmacol.* 2021 Sep 14;12:739637.
22. Nagaraju B, Anilkumar KV. Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits. *Indian J Pharmacol* 2021;53:465-70.
23. Nagaraju B, Anilkumar KV. Effect of Olmesartan on pharmacodynamic and pharmacokinetics of glimepiride and metformin combination in animal models. *Indian Drugs.*2020;57:60-8.
24. Nagaraju B, Anilkumar KV. Influence of Telmisartan on Pharmacodynamic and Pharmacokinetic Properties of Glimepiride-metformin Combination using Rodent and Non-Rodent Models. *Indian J of Pharmaceutical Education and Research.*2021;55(4):1060-5.

25. Salim H, Jones AM. Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions. *Br J Clin Pharmacol.* 2022 Nov;88(11):4812-27.

AJPTR

American Journal of PharmTech Research



PEER-REVIEWED

BIMONTHLY

RAPID PUBLICATION

SUBMIT YOUR MANUSCRIPT

Submit your manuscript at:
editor@ajptr.com

Visit our site:
<https://ajptr.com/>